



ESPS JOURNAL EDITOR-IN-CHIEF'S REVIEW REPORT

Name of journal: World Journal of Ophthalmology

ESPS manuscript NO: 15845

Title: Advances in retinal imaging modalities: Challenges and opportunities

Journal Editor-in-Chief (Associate Editor): Umit Ubeyt Inan

Country: Turkey

Editorial Director: Xiu-Xia Song

Date sent for review: 2016-03-14 17:56

Date reviewed: 2016-03-17 05:55

ACADEMIC CONTENT EVALUATION	LANGUAGE QUALITY EVALUATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Revision
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		

JOURNAL EDITOR-IN-CHIEF (ASSOCIATE EDITOR) COMMENTS TO AUTHORS

The authors reviews the imaging modalities in retinal disease. The theme of the review is good. I do not agree that some centers performs FFA and ICG simultaneously in routinely. It is true that PCV is common in Far-East countries, and ICG is performed in more patients. Glaucoma modules measure peripapillary RNFL not ONH thickness. Glaucoma modules also measure ganglion cell-inner plexiform layer complex. It can also make posterior pole asymmetry analysis. They can also show progression by an analysis after several time point measurements. It would be nice if more information on OCT Angiography (OCT-A) were given albeit an image from OCT-A is depicted (when considering the title of the review). I think that trade names should not be given in some imaging categories in which several devices is exist, or all trade name be given in parenthesis. For example fundus cameras and FFA devices; Intraoperative OCT devices are exist alt least for three company (HaagStreit, Zeiss (Rescan model), and Leice (bioptigen OCT)) The authors should also clearly declare financial relationship in any company, if any.